Hospital Angelina Caron, of Campina Grande do Sul, Paraná, is the latest Brazilian hospital to join Clinerion’s network of partner hospitals on its Patient Network Explorer platform. Hospital Angelina Caron has nearly one million patients and specializes in cardiology, ophthalmology, pediatrics and neonatology, gynecology and obstetrics, orthopedics, transplants, obesity and digestive system, oncology, neurology, cardiology, nephrology, vascular and endovascular surgery. The hospital has run 10 international trials per year for the past five years.
Clinerion’s Patient Network Explorer helps partner hospitals be visible to pharmaceutical companies seeking suitable patients and sites for their clinical trials. Leveraging patient medical data, queries based on trial protocols may be sent to partner hospitals to assess the count of eligible patients in their electronic health records. All patient data is de-identified and remains under the control of the hospital and inside its IT infrastructure. However, Clinerion’s patented technology also enables authorized trial staff at the hospital to re-identify the patient for the purpose of trial recruitment, while maintaining strict personal data privacy standards.
“With the Clinerion database system, there will be a great progress in research at our center, facilitating patient selection and increasing our effectiveness. Today, a database and facilitating access to information are fundamental to the evolution of research”, says Dalton B. Precoma MD, PhD, cardiologist of Hospital Angelina Caron.
“We are so pleased that our patient coverage in Brazil is expanding by leaps and bounds,” says Ian Rentsch, CEO of Clinerion. “It shows that the benefits of visibility to pharmaceutical trial sponsors that we offer to hospitals running international clinical trials are well understood and accepted.”
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Managing Side Effects and Dosing in Off-Label GLP-1 Use with Help from Real-World Evidence
July 18th 2025Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world data is helping researchers navigate gastrointestinal side effects, dose flexibility, and long-term tolerability in off-label GLP-1 use.
Anselamimab Misses Primary Endpoint in Phase III CARES Trials for AL Amyloidosis
July 17th 2025In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a prespecified subgroup analysis revealed meaningful improvements in survival and cardiovascular outcomes.